Šalis: Pietų Afrika
kalba: anglų
Šaltinis: South African Health Products Regulatory Authority (SAHPRA)
Adcock
INDICATIONS [/za_130.html#1] [/za_130.html#1] [/za_130.html#1] CONTRA-INDICATIONS [/za_130.html#1] [/za_130.html#1] DOSAGE [/za_130.html#1] [/za_130.html#1] SIDE-EFFECTS [/za_130.html#1] [/za_130.html#1] [/za_130.html#1] PREGNANCY [/za_130.html#1] [/za_130.html#1] OVERDOSE [/za_130.html#1] IDENTIFICATION [/za_130.html#1] [/za_130.html#1] PATIENT INFORMATION ADCO-RETIC TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): ADCO-RETIC TABLETS COMPOSITION: Each tablet contains 5 mg AMILORIDE hydrochloride, and 50 mg HYDROCHLOROTHIAZIDE . PHARMACOLOGICAL CLASSIFICATION: A 18.1 Diuretics PHARMACOLOGICAL ACTION: ADCO-RETIC TABLETS have diuretic and antihypertensive effects, combining the natriuretic action of hydrochlorothiazide, with the potassium conserving property of amiloride hydrochloride. The mild diuretic action of amiloride hydrochloride is additive to the natriuretic and diuretic activity of the thiazide. INDICATIONS: ADCO-RETIC TABLETS are indicated in the treatment of patients with oedema of cardiac decompensation or associated with hepatic cirrhosis and corticosteroid therapy. They are also indicated in the treatment of patients with essential hypertension. CONTRA-INDICATIONS: Hyperkalaemia: ADCO-RETIC TABLETS should not be used in the presence of elevated plasma potassium levels (interpreted as over 5,5 mmol per L). Antikaliuretic Therapy or Potassium Supplementation: Other antikaliuretic agents and potassium supplements are contra-indicated in patients receiving ADCO-RETIC TABLETS due to the potassium-sparing effect of amiloride hydrochloride (such combination therapy is commonly associated with rapid increases in plasma potassium levels). Impaired Renal Function: Anuria, acute renal failure, severe progressive renal disease and diabetic nephropathy are co Perskaitykite visą dokumentą